Australia’s growing reliance on high-cost biologics for inflammatory skin diseases has placed significant pressure on its ...

While Big Pharma seems ready to weather the tariff storm, independent pharmacists and makers of generic drugs — which account ...

Bayer’s consumer health business benefits from a narrow economic moat, largely because of its strong brand power. Consumers continue to pay a premium for Aspirin, Aleve, and other over-the-counter ...

Aurobindo Pharma's CuraTeQ Biologics receives marketing authorization for Zefylti filgrastim biosimilar in the UK and EU.

The biosimilars business accounted for 58% of Biocon's overall revenue in FY25. Biocon Biologics had said it would likely ...

Novo Nordisk A/S’s decision to stop making insulin pens will narrow treatment options for children with diabetes unless ...

The cost of prescription drugs have risen rapidly despite policymakers pledging to fix the issue. They climbed nearly 40% since 2014, according to data from GoodRx.

Indian generic drugmakers typically operate on thin EBITDA margins of 5-15 percent on average for their base business in US, ...

The Company achieved a 29% reduction in absolute scope 1 and 2 greenhouse gas emissions from 2019 levels, surpassing its target of 25% by 2025, ahead of schedule Teva launched two new programs to help ...

This initiative aligns with Sandoz’s ongoing efforts to support Egypt’s Vision 2030 and local healthcare authorities’ ...

Research conducted at the Suez Canal University endocrinology outpatient clinic in Ismailia City, Egypt and released in 2024, ...

Biocon plans a $150 million capital expenditure, allocating $100 million to biologics, primarily enhancing Malaysian ...